Compare PAYO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYO | VERA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | 2540 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.9B |
| IPO Year | N/A | 2021 |
| Metric | PAYO | VERA |
|---|---|---|
| Price | $4.76 | $38.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $7.69 | ★ $81.30 |
| AVG Volume (30 Days) | ★ 4.1M | 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $9.77 | $416.83 |
| P/E Ratio | $30.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.08 | $18.53 |
| 52 Week High | $7.67 | $56.05 |
| Indicator | PAYO | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 47.31 | 42.17 |
| Support Level | $4.32 | $37.36 |
| Resistance Level | $4.86 | $43.21 |
| Average True Range (ATR) | 0.20 | 2.33 |
| MACD | 0.07 | 0.10 |
| Stochastic Oscillator | 59.33 | 25.09 |
Payoneer Global Inc is a financial technology company that enables small and medium-sized businesses (SMBs) to grow internationally through its diversified cross-border payments platform. It connects businesses, professionals, countries, and currencies, reducing the complexity of commerce and enabling customers to pay and get paid as easily as locally. The company offers a financial stack that includes cross-border AR/AP capabilities, funds management, working capital solutions, multicurrency accounts, and workforce management services. Its fully hosted platform provides multiple payment options with minimal integration, along with back-office functions and customer support. The company operates in Israel, the United States, and other countries.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.